For medtech founders and private clinical groups

Medical AI consultant in the UK, one named advisor

Independent validation of clinical AI models, and senior advisory for the teams building and buying them. One named principal with an Oxford DPhil in AI and Medical Informatics, whose clinical decision support research has been cited over 200 times.

The case for a medical AI consultant in the UK

Thirty-seven per cent of UK physicians now use AI in clinical practice at least monthly (Royal College of Physicians, 2026). Seventy-nine per cent say they need training; only six per cent have access to it. Seventy-four per cent cite lack of clinical AI expertise inside their organisation as the top deployment barrier. Demand has lifted sharply, whereas the advisory capacity inside most UK clinical and medtech teams has not moved at the same speed.

The single named advisor role closes that gap without a full-time CAO hire. The specific expertise that is scarce is the ability to read a clinical model the way a methodologist reads a trial: to see that an AUROC of 0.91 was obtained with the same patients on both sides of the split, that a calibration curve has never been plotted, or that a vendor validated on the site that produced the training data and called it external. Engagements run monthly on a rolling retainer, or one-off on a scoped validation.

UK clinical AI, 2026 baseline

Six data points grounded in Royal College of Physicians 2026, the two 2025 peer-reviewed UK GP generative-AI surveys, and NHS England trust deployments. These are the numbers a medtech founder or clinical lead wants cited back in a scoping conversation.

37%
of UK physicians now use AI at least monthly in clinical practice (16% daily, 15% weekly, 6% monthly)
79%
of physicians say they need AI training, against the 6% who have access to it. A 73-point gap between demand and supply.
74%
of UK physicians cite lack of clinical AI expertise inside their organisation as a top deployment barrier
25%
of UK GPs now use generative AI in clinical practice, up from 20% in 2024
95%
of UK GPs received no professional employer-provided training on generative AI; 85% report no employer encouragement
£1.7M
year-one savings from a single CDS deployment at Salford Royal; a reference for what good looks like

The figures above show three things. UK clinical AI adoption has crossed the threshold, with physicians and GPs pulling tools into the workflow faster than their organisations can supply governance. The training and expertise gap is a single-advisor-shaped hole: most teams do not need a full consulting pyramid, they need one credible named principal. And the upside, when deployment is done properly, is quantified: £1.7 million in year one at a single NHS trust from a single pathway.

Engagement patterns for a medical AI consultant

Four shapes of work medtech founders, private clinical groups, and individual clinical leads most often ask a named medical AI consultant in the UK to take on.

Fractional Chief AI Officer for healthcare

2 to 4 days per month of senior advisory for a digital-health founder, medtech scale-up, or private hospital group. Deliverable: monthly written check-ins, quarterly board-ready summaries, and continuous coverage of model selection, evaluation design, independent validation, and technical input to the clinical governance forum.

Clinical-AI validation

A 3-5 week engagement for a medtech or pharma team preparing a clinical pilot. Deliverable: an independent report on patient-level leakage, calibration, discrimination, subgroup performance, missing-data behaviour, and hallucination rate where the system is generative, with a revision path for each gap found.

Independent review of a vendor model

A 2-4 week engagement for a trust, private group, or procurement lead evaluating a commercial AI product. Deliverable: a written assessment of what the vendor evidence actually establishes, which claims rest on internal validation only, and the specific questions to put to the supplier before signing.

Clinical and medical education AI teaching

A 2-day workshop plus written playbook for a clinical leadership team, a postgraduate teaching faculty, or a royal college education lead. Deliverable: a working understanding of how clinical AI is evaluated, how to read a model card or a vendor performance claim, and which failures the headline metric hides.

Six questions an independent validation asks

Most clinical AI models that disappoint in deployment were not badly built. They were evaluated in a way that could not have detected the problem. These are the checks that separate a model which works from a model whose reported numbers look like it works, and the specific failure each one catches.

CheckThe question it puts to the modelWhat failing it means
Patient-level separationDo any records from the same patient appear in both the training and the test set?The reported accuracy is partly memorisation. Repeat measurements and multi-episode patients are the usual route in, and the inflation is largest for exactly the sickest patients.
Calibration, not just rankingWhen the model says 0.7, does the event happen about 70 per cent of the time?A model can rank well and still be badly calibrated. Any threshold, triage rule or resource decision built on the raw score is then miscounted, even though AUROC looks healthy.
Subgroup performanceDoes performance hold by age, sex, ethnicity, comorbidity burden and site?A strong pooled figure can hide a subgroup where the model is no better than chance. Aggregate metrics are structurally incapable of surfacing this.
External validationHas the model been evaluated on data from a site that contributed nothing to training?Internal cross-validation measures consistency, not generalisation. Coding practice, case mix and equipment differ per site, and performance usually drops on first contact with a new one.
Missing data behaviourWhat does the model do when a clinical variable is absent, and is absence itself informative?Missingness in clinical data is rarely random: an untaken test is a decision. Imputation that ignores this quietly encodes the ordering behaviour of the training site.
Drift and traceabilityAfter deployment, which version is live, against which validation run, and what would show degradation?Models degrade silently under distribution shift. Without version-to-validation traceability and a monitored metric, the first evidence of a problem is a clinical incident.

Clinical language-model evaluation. A retrieval-backed clinical assistant needs evaluation criteria designed for its intended task. Berkan Sesen's study with Joshua Au Yeung and Elham Asgari, published in BMJ Digital Health & AI in November 2026, compared a language model with RAG and GraphRAG on simulated chronic kidney disease cases. It assessed clinical correctness, patient specificity and clarity separately. The study provides evidence about guideline-based answer generation. Testing in clinical practice remains necessary before deployment.

The engagement process

Engagements start with a 30-minute intro call with the clinical lead, digital-health founder, or CTO. If the shape of work is clear we send a scoped proposal within 48 hours. If it is not, we run a short paid scoping exercise before committing to a number.

  1. Scope. 30-minute intro with the clinical or founding lead plus a written brief.
  2. Evidence review. A short written assessment of what the existing evaluation actually establishes, which of the six checks above it covers, and which of them nobody has run yet.
  3. Discovery. Structured review of current clinical-AI footprint, product roadmap, and any retrospective clinical data.
  4. Deliverable. Whichever engagement pattern fits: retainer, validation, evidence map, or workshop.
  5. Continuity (optional). A time-boxed engagement can convert to a monthly retainer covering monthly check-ins and board-ready summaries.

Boutique vs Big-4

Big-4 firms can ship a health-informatics partner into any engagement, but the medical AI consultant role is specifically the one a medtech founder or small clinical group cannot afford to staff as a full consulting pyramid. What they can afford, and what the RCP 2026 data says they need, is one named principal with clinical-AI publications, an Oxford clinical-AI doctorate, and current applied LLM research, on a monthly retainer.

The boutique model inverts the incentives. One named advisor whose credentials carry the work. Validation reports and board papers written by the person who will defend them at the pilot committee or the investor meeting, not by an associate who has never had a clinical model of their own survive peer review.

The principal advisor

Berkan Sesen holds an Oxford DPhil in AI and Machine Learning, Medical Informatics (Clarendon Scholar, supervised in Sir Michael Brady's group), an Oxford MSc in Biomedical Engineering (Distinction), and a 2012 research visit to Stanford Biomedical Informatics. The doctoral work built Bayesian survival and treatment-recommendation models on the English Lung Cancer Database, so the training set was real patient outcome data rather than a benchmark. It produced "Bayesian Networks for Clinical Decision Support in Lung Cancer Care" (PLOS One 2013, cited over 200 times), "Survival Prediction and Treatment Recommendation with Bayesian Techniques" (AMIA Annual Symposium 2012), and "Lung Cancer Assistant" (Journal of the Royal Society Interface 2014), and won the British Thoracic Oncology Group Best Research Prize in 2013, judged by respiratory oncology clinicians rather than by a machine learning panel. Current clinical work includes a RAG and GraphRAG evaluation for guideline-based decision support in chronic kidney disease, published in BMJ Digital Health & AI in November 2026. He also co-founded Recallify, funded by NIHR and Innovate UK, which won the UKABIF Innovation Award in 2024 and runs active clinical and educational studies with senior NHS neurologists and educational psychologists. A decade in financial services (UBS, Citigroup, JP Morgan Asset Management), sell-side and buy-side both, adds a second regulated-sector lens and a P&L-literate one for medtech founders making commercial decisions alongside clinical ones. Read the full background at /about/founder. To have one named model or product independently validated, see the clinical decision support consulting practice. For trust-wide NHS strategy, see the AI strategy for hospitals and NHS trusts practice.

Two of those went further than a publication. Lung Cancer Assistant was built, piloted at three sites, and evaluated end to end against real patient outcome data; clinicians used it. Recallify is in clinical use today. The finance years are a different setting for the same problem: models running in production under formal model-risk governance, where a silent degradation is an incident with a report attached rather than a number that moved.

Interactive tools

Free tools built to solve concrete questions that come up during a medical AI consulting engagement:

  • LLM cost calculator. For costing an LLM-backed clinical vendor contract across providers before regulated-sector procurement.
  • Full tools catalogue. Calculators and visualisers for statistics, survival analysis, and Bayesian inference used in clinical-AI validation work.

Related reading

Next step

30-minute intro call with the clinical lead, digital-health founder, or CTO. A scoped proposal within 48 hours if the shape of work is clear, or a short paid scoping exercise if it is not.

Book an intro call

Stay in the loop

Get notified when new tutorials and deep-dives are published. No spam, unsubscribe anytime.

Frequently Asked Questions